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Statement of findings
We propose that the phenomenon of X-chromosome inactivation in females may constitute
a risk factor for loss of T-cell tolerance; specifically, skewed X-chromosome inactivation in
the thymus may lead to inadequate thymic deletion. Using a DNA methylation assay, we
have examined the X-chromosome inactivation patterns in peripheral blood from normal
females (n = 30), and female patients with a variety of autoimmune diseases (n = 167). No
differences between patients and controls were observed. However, locally skewed
X-chromsome inactivation may exist in the thymus, and therefore the underlying hypothesis
remains to be disproved.
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AR = androgen receptor; PCR = polymerase chain reaction; PLP = proteolipid protein.
Introduction: A reduction in the sex ratio (male : female) is
characteristic of most autoimmune disorders. The increased
prevalence in females ranges from a modest 2:1 for multiple
sclerosis [1], to approximately 10:1 for systemic lupus
erythematosus [2]. This tendency toward autoimmunity in
females is often ascribed to hormonal differences, because in a
number of experimental disease models estrogens exacerbated
disease, and androgens can inhibit disease activity [3,4].
However, human studies have failed to demonstrate a clear-cut
influence of hormonal environment on disease susceptibility to
lupus or other autoimmune disorders. In addition, many
childhood forms of autoimmunity, such as juvenile rheumatoid
arthritis, exhibit female predominance [5]. Interestingly, juvenile
(type 1) diabetes is an exception to this general trend, with a sex
ratio close to 1 in most studies [6]. Therefore, it is reasonable to
consider alternative explanations for the increased prevalence of
autoimmune diseases in human females.
A unifying feature of autoimmune disorders appears to be the
loss of immunologic tolerance to self-antigens, and in many of
these diseases there is evidence that T-cell tolerance has been
broken. The most profound form of T-cell tolerance involves
deletion of potentially self-reactive T cells during thymic
selection. Thus, lack of exposure to a self-antigen in the thymus
may lead to the presence of autoreactive T cells and may
increase the risk of autoimmunity. An elegant example of this
has recently been reported [7].
The existence of X-chromosome inactivation in females offers a
potential mechanism whereby X-linked self-antigens may
escape presentation in the thymus or in other peripheral sites
that are involved in tolerance induction. Early in female
http://arthritis-research.com/content/2/5/399Arthritis Research    Vol 2 No 5 Chitnis et al
development, one of the two X chromosomes in each cell
undergoes an ordered process of inactivation, with subsequent
silencing of most genes on the inactive X chromosome [8]. This
phenomenon occurs at a very early embryonic stage [9], and
thus all females are mosaic and may occasionally exhibit
extreme skewing towards one or the other parental X
chromosome. In theory, this may result in a situation in which
polymorphic self-antigens on one X chromosome may fail to be
expressed at sufficiently high levels in a tolerizing compartment,
such as the thymus, and yet may be expressed at a
considerable frequency in the peripheral soma. Thus, females
may be predisposed to a situation in which they can
occasionally express X-linked autoantigens in the periphery to
which they have been inefficiently tolerized. Stewart [10] has
recently speculated that such a mechanism may play a role in
the predisposition to systemic lupus.
This hypothesis predicts that females with autoimmunity may
be particularly prone to this mechanism of ‘inadequate
tolerization’ by virtue of extremely skewed X-chromosome
inactivation. We therefore performed a comprehensive analysis
of X-chromosome inactivation patterns in populations of
females with multiple sclerosis, systemic lupus erythematosus,
juvenile rheumatoid arthritis, and type 1 (insulin-dependent)
diabetes mellitus, and in female control individuals. The results
do not provide support for a major role for skewed X-
chromosome inactivation in female predisposition to
autoimmunity; however, neither is the underlying hypothesis
disproved by the present data.
Materials and method: DNA was obtained from female
patients from the following sources: 45 persons with juvenile
diabetes seen at the Virginia Mason Research Center in
Seattle, Washington; 58 multiple sclerosis patients seen at the
New York Hospital Multiple Sclerosis Center; 46 patients with
systemic lupus erythematosus seen at the Hospital for Special
Surgery (New York); 18 patients with juvenile rheumatoid
arthritis seen at the Children’s Hospital Medical Center in
Cleveland. In addition, 30 healthy age-matched females were
studied as normal controls.
Employing a modification of previously described methods [11],
we utilized a fluorescent Hpa II/PCR assay of the androgen
receptor (AR) locus to assess X-chromosome inactivation
patterns. The AR gene contains a polymorphic CAG repeat,
which is flanked by Hpa II sites. These Hpa II sites are methylated
on the inactive X chromosome, and are unmethylated on the
active X chromosome. By performing PCR amplification across
this region after cutting with the methylation-sensitive enzyme
Hpa II, the relative amounts of the methylated AR alleles can be
quantitatively determined with a high degree of accuracy;
variance on repeated assays is approximately 4% [12].
Skewing of X-chromosome inactivation is expressed as
percentage deviation from equal (50:50) inactivation of the
upper and lower AR alleles. Therefore, the maximal possible
deviation is 50%, in which case all of the X chromosomes
bearing one of the AR alleles are inactivated.
Results: We examined X-chromosome inactivation patterns in
several different populations. The results are summarized in
Fig. 1. A wide range of X-inactivation skewing was observed in
all five groups. Approximately 5% (nine out of 197) of individuals
exhibited extreme skewing (greater than 40% deviation from a
50:50 distribution). However, there was no difference between
the groups, either in the overall mean skewing, or in the fraction
of individuals with extreme skewing (>40%).
Although the present study was not initiated in order to examine
allelic variation in the AR gene per se, the data provide an
opportunity to address this question. Excessively long CAG
repeats in the AR are a rare cause of spinal-bulbar muscular
atrophy [13], and AR repeat length appears to have an influence
on the biology of certain tumors [14,15]. In this context, it has
been shown that transcription of AR correlates inversely with
repeat length [16]. We therefore compared AR repeat length in
control individuals and patients with autoimmunity. No
differences were observed for mean repeat length, or for
maximum and minimum repeat length, among the five groups.
Discussion: The reason for the female predominance in most
autoimmune diseases remains obscure. The present study was
initiated in order to address the hypothesis that a nonhormonal
mechanism related to X inactivation might be involved. The
hypothesis rests on the idea that skewing of X inactivation
might lead to a deficiency of tolerance induction in the thymus,
particularly with respect to polymorphic X-linked autoantigens.
The hypothesis predicts that skewed X inactivation would be
more prevalent in females with autoimmune diseases than in
female control individuals. This was not observed.
Nevertheless, these negative data do not rule out a role for X
inactivation in female predisposition to loss of tolerance. A
general model for how this mechanism might operate is shown
in Fig. 2. Thymocytes undergo selection in the thymic
parenchyma and, in the case of negative selection, the selecting
elements appear to be derived from the bone marrow and
consist mainly of thymic dendritic cells. If the thymic dendritic
cell population exhibits random X inactivation, it is highly likely
that differentiating thymocytes will contact dendritic cells that
Figure 1
Comparison of skewing of X inactivation in normal female control
individuals, and patients with various autoimmune diseases. Each dot
represents one individual. The mean values for degree of skewing of X-
inactivation are indicated for each population.
10
20
30
40
50
Normal
n=30
Systemic Lupus
Erythematosus
n=46
Juvenile
Diabetes
n=45
Multiple
Sclerosis
n=58
Degree
of Skewing of
X-Inactivation
(%)
19.52
14.43
17.90
13.70 13.73
Juvenile
Rheumatoid
Arthritis
n=18http://arthritis-research.com/content/2/5/399
express self-antigens on both X chromosomes. This situation is
outlined schematically on the left side of Fig. 2. However, if there
is extremely skewed X inactivation in the thymic dendritic cell
population, a particular thymocyte might not come into contact
with dendritic cells that express one of the two X chormosomes.
This would lead to a situation where T cells may undergo thymic
maturation without having been negatively selected for antigens
that are expressed on the predominantly inactive X
chromosome. This situation is shown on the right side of Fig. 2.
In order for this mechanism to be physiologically relevant, some
assumptions must be made. First, defective tolerance from
skewed X inactivation should only be directed at X-linked
antigens that are polymorphic, and for which the individual is
heterozygous. Thus, this mechanism would not be expected to
lead to lack of tolerance commonly, unless there are at least
several highly polymorphic X-linked autoantigens in the
population that are involved in thymic deletion events. Second,
if this actually leads to autoimmunity, it also predicts that the
initial break in tolerance that leads to disease should involve an
X-linked autoantigen that is expressed in a peripheral
nontolerizing site or circumstance.
A recent report [7] has elegantly demonstrated the importance
of thymic deletion events in predisposition to autoimmune
disease. The proteolipid protein (PLP) autoantigen is
expressed in alternatively spliced forms, which exhibit tissue
specific expression. A nonspliced variant is expressed in
peripheral neural tissue. However, in the thymus a splice variant
results in the lack of thymic expression of an immunodominant
peptide. This results in loss of tolerace of T cells to this
peptide, presumably on the basis of lack of thymic deletion of
thymocytes that are reactive with this antigen. Interestingly,
PLP is encoded on the X chromsome. However, there is no
evidence that genetic polymorphisms control the level splicing
of PLP within the thymus. Nevertheless, these data illustrate
the potential importance of deficiencies in thymic deletion for
autoimmune T-cell reactivity.
The present results suggest that if skewed X inactivation is
relevant to thymic tolerance induction, then the effect does not
depend on global skewing of X-chromosome inactivation, at
least in the hematopoietic compartment. In this study we
examined X-inactivation patterns in peripheral blood
mononuclear cells, and the results should reflect the state of X
inactivation in all mesenchymal tissues, including dendritic
cells. X inactivation occurs at a very early time point in
development, and thus the results in one tissue should reflect
the general situation in the rest of the body. However, there
may be exceptions to this. We have occasionally observed
differences in X-inactivation patterns between buccal mucosa
Figure 2
A model showing the consequence of skewed X-chromosome inactivation on tolerance induction in the thymus. Thymocytes enter the thymus and
proceed on a pathway that exposes them to thymic-deleting elements, mainly dendritic cells in the thymic medulla. Dendritic cells are schematically
illustrated here as grey or black, depending on which of the two parental X chromosomes are predominantly active in each cell. On the left hand
side of the figure, transiting thymocytes will be exposed to dendritic cells that express both parental X chromsomes, and thus will be tolerant (ie
deleted) to X-linked antigens from both parents. On the right hand side of the figure, transiting thymocytes will likely be exposed only to the ‘grey’
dendritic cells, which express only one of the two parental X chromosomes. Thus, T cells that exit the thymus will not be tolerized to X-linked
antigens from the other parent (the ‘black’ dendritic cells).
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A reduction in the sex ratio (male : female) is characteristic
of most autoimmune disorders. The increased prevalence
in females ranges from a modest 2:1 for multiple sclerosis
[1], to approximately 10:1 for systemic lupus erythemato-
sus [2]. This tendency towards autoimmunity in females is
often ascribed to hormonal differences because, in a
number of experimental disease models, estrogens exac-
erbate disease and androgens can inhibit disease activity
[3,4]. However, human studies have failed to demonstrate
a clear-cut influence of hormonal environment on disease
susceptibility to lupus or other autoimmune disorders. In
addition, many childhood forms of autoimmunity, such as
juvenile rheumatoid arthritis, exhibit female predominance
[5]. Interestingly, juvenile (type 1) diabetes is an exception
to this general trend, with a sex ratio close to 1 in most
studies [6]. Therefore, it is reasonable to consider alterna-
tive explanations for the increased prevalence of autoim-
mune diseases in human females.
A unifying feature of autoimmune disorders appears to be
the loss of immunologic tolerance to self-antigens, and in
many of these diseases there is evidence that T-cell toler-
ance has been broken. The most profound form of T-cell
tolerance involves deletion of potentially self-reactive T
cells during thymic selection. Thus, lack of exposure to a
self-antigen in the thymus may lead to the presence of
autoreactive T cells and increase the risk of autoimmunity.
An elegant example of this has recently been reported [7].
The existence of X-chromosome inactivation in females
offers a potential mechanism whereby X-linked self-antigens
may escape presentation in the thymus or in other periph-
eral sites that are involved in tolerance induction. Early in
female development, one of the two X chromosomes in
each cell undergoes an ordered process of inactivation,
with subsequent silencing of most genes on the inactive X
chromosome [8]. This phenomenon occurs at a very early
embryonic stage [9], and thus all females are mosaic and
may occasionally exhibit extreme skewing towards one or
the other parental X chromosome. In theory, this may result
in a situation in which polymorphic self-antigens on one X
chromosome may fail to be expressed at sufficiently high
levels in a tolerizing compartment, such as the thymus, and
yet may be expressed at considerable frequency in the
peripheral soma. Thus, females may be predisposed to a sit-
uation in which they can occasionally express X-linked
autoantigens in the periphery to which they have been ineffi-
ciently tolerized. Stewart [10] has recently speculated that
such a mechanism may play a role in the predisposition to
systemic lupus.
This hypothesis predicts that females with autoimmunity
may be particularly prone to this mechanism of
‘inadequate tolerization’ by virtue of extremely skewed
X-chromosome inactivation. We therefore performed a
comprehensive analysis of X-chromosome inactivation pat-
terns in populations of females with multiple sclerosis, sys-
temic lupus, juvenile rheumatoid arthritis, and type 1
(insulin-dependent) diabetes mellitus, and in female
control individuals. The results do not provide support for
a major role for skewed X-chromosome inactivation in
female predisposition to autoimmunity; however, neither is
the underlying hypothesis disproved by our data.
Materials and method
Subjects
DNA was obtained from female patients from the following
sources: 45 persons with juvenile diabetes seen at the
Virginia Mason Research Center in Seattle, Washington;
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(an ectodermally derived tissue) and peripheral blood in the
same individiual (unpublished observations). This could be a
chance event, or it may result from selection for certain X-linked
alleles during embryonic development, as has been described
in carriers of X-linked immunodeficiencies [17].
Another consideration is that certain tissue microenvironments
may be derived from very small numbers of founder cells, and
thus may exhibit skewed utilization of one or the other X
chromosome, even if the tissue as a whole is not skewed. This
situation could vary over time. Thus, there may be time points at
which certain thymic microenvironments are populated by
dendritic cells that, for stochastic reasons, all utilize the same X
chromosome. This would create a ‘window of opportunity’ in
which a given thymocyte, in a given selecting location, could
escape negative selection by antigens on the inactive X
chromosome. The likelihood of this happening would obviously
depend on the number of dendritic cells that are usually
contacted by a thymocyte during thymic selection. There is
limited information on this point, although Stewart [10] has
theorized that this number may be as low as 15. If this is the
case, then escape from thymic deletion may still occur in females
who are heterozygous for a relevant X-linked antigen, even if the
hematopoietic cells in general do not exhibit extreme skewing.
In conclusion, we suggest that X-chromosome inactivation
needs to be considered as a potential factor in the
predominance of females in most autoimmune diseases. Our
inability to show an increase in X-chromosome skewing in
females with autoimmunity does not eliminate this as an
etiologic contributor to loss of immunologic tolerance. Future
experiments must be directed at a detailed analysis of tissue
patterns of X inactivation, as well as at a search for potential X-
linked autoantigens.58 multiple sclerosis patients seen at the New York Hos-
pital Multiple Sclerosis Center; 46 patients with systemic
lupus erythematosus seen at the Hospital for Special
Surgery (New York); 18 patients with juvenile rheumatoid
arthritis seen at the Children’s Hospital Medical Center in
Cleveland. In addition, 30 healthy age-matched females
were studied as normal controls.
Hpa II/polymerase chain reaction assay for X-chromosome
inactivation
A modification to a previously described assay for AR
methylation [11] was used for these studies. In the normal
females the AR gene is methylated on the inactive X chro-
mosome and is undermethylated on the active X chromo-
some. Furthermore, the presence of a highly polymorphic
triplet repeat within the AR gene allows for the discrimina-
tion of each X chromosome in most female subjects
(Fig. 3). Thus, allele-specific methylation patterns can be
distinguished using this gene.
Genomic DNA (approximately 200 ng) was digested
overnight using a methylation-sensitive restriction enzyme
HpaII, as per the manufacturer’s instructions (Gibco BRL,
Rockville, MD, USA). A mock sample as control was pre-
pared simultaneously without the HpaII enzyme. After the
digestion the samples were boiled for 10 min to inactivate
the enzyme. PCR amplification was performed, with final
concentration of the digest equivalent to approximately
100 ng of the DNA, 1 × PCR bufferII (Perkin-Elmer, Foster
City, CA, USA), 2.5 mmol/l MgCl2, and amplitaq gold
1.25 units.
Primers used were AR1 (5¢-TCCAGAATCTGTTCCA-
GAGCGTGC-3¢) and AR2 (5¢-GCTGTGAAGGTTGCT-
GTTCCTCAT-3¢). These primers flank the triple repeat CAG
and the HpaII sites in the first exon of the AR gene (Fig. 3).
The AR1 primer was fluorescence labeled with 6-Fam and
TET. The 6-Fam-AR1 and the TET-AR1 were used for mock
and HpaII-digested samples, respectively. This combination
allowed simultaneous analyses of the PCR products of the
HpaII- and mock-treated samples using the ABI310 Genetic
Analyzer (Perkin-Elmer). The final concentration of the AR1
primer was 3 pmol 6-Fam-AR1 + 7 pmol unlabelled AR1 and
10 pmol of unlabeled AR2 in a 50 ml reaction.
The cycling conditions were as follows: denaturation at
95°C/12 min to activate the amplitaq gold, followed by 35
cycles of denaturation at 95°C/45 s, annealing at
60°C/30 s and extension at 72°C/30 s. After 35 cycles, the
final extension was done at 72°C/10 min. The PCR prod-
ucts of each sample (mock and HpaII) were diluted 1:10 in
the same vial. One microliter of the diluted product was then
added to a mixture containing 12 ml deionized formamide
and 0.5 ml molecular weight standard GS 350 TAMRA. The
vials were denatured at 95°C/5 min, cooled on ice, and
resolved using a 310 Genetic Analyzer (Perkin-Elmer).
Calculations for percentage of skewing of X inactivation
Two peaks corresponding to two alleles were obtained
from the 310 Genetic Analyzer for each mock- and HpaII-
treated sample. The relative intensity of the larger AR allele
(higher molecular weight, peak 2) with respect to the
smaller AR allele (low molecular weight, peak 1) was cal-
culated and expressed as the ratio R (peak 2 area/peak 1
area). The ratios in the mock-digested (RM) and HpaII-
digested (RH) samples were calculated separately, and
were then averaged for each of the two sets of duplicate
samples. For each individual, a normalized ratio
(RN =R H/RM) was calculated to correct for occasional
minor variation in efficiency of amplification of the two AR
alleles. This normalized ratio was used to determine the
percentage of inactivation of the X chromosome bearing
the larger AR allele: percentage inactivation = [RN/(RN +
1)] × 100. The degree of skewing was calculated by sub-
tracting 50 from the observed degree of inactivation.
Results
Fluorescent Hpa II/polymerase chain reaction assay for X-
chromosome inactivation
Employing a modification of previously described methods
[11], we utilized a fluorescent Hpa II/PCR assay of the AR
locus to assess X-chromosome inactivation patterns. As
shown in Fig. 3, the AR gene contains a polymorphic CAG
repeat that is flanked by Hpa II sites. These Hpa II sites
are methylated on the inactive X chromosome, and are
unmethylated on the active X chromosome. By performing
PCR amplification across this region after cutting with the
methylation-sensitive enzyme Hpa II, the relative amounts
of the methylated AR alleles can be quantitatively deter-
mined with a high degree of accuracy; variance on
repeated assays is approximately 4% [12].
Two examples of this assay are shown in Fig. 4. In Fig. 4a,
an individual with equivalent methylation of both AR alleles
is shown. In this case, the relative peak intensity is equiva-
lent in the mock-digested and Hpa II-digested samples. In
Fig. 4b, an individual with extremely skewed X inactivation
is shown, in whom the lower allele (271 bp) is relatively
over-methylated compared with the upper (284 bp) allele.
Thus, the X chromosome bearing the lower allele is prefer-
entially inactivated. As described in the Materials and
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Figure 3
Schematic map of a portion of the first exon of the AR gene. The
polymorphic CAG triplet repeat is flanked by HpaII sites, and the
relative locations of primers AR1 and AR2, used for the PCR assay,
are indicated.
(CAG)n
Hpa II
primer
AR-1
primer
AR-2 Hpa IImethod section, all assays were normalized to the mock
results and performed in duplicate. Skewing of X-chromo-
some inactivation is expressed as a percentage deviation
from equal (50:50) inactivation of the upper and lower AR
alleles. Therefore, the maximal possible deviation is 50%,
in which case all of the X chromsomes bearing one of the
AR alleles are inactivated.
Comparison of X-chromosome inactivation patterns in
normal females and females with autoimmune diseases
We examined X-chromosome inactivation patterns in
several different populations. The results are summarized
in Fig. 1. A wide range of X-inactivation skewing was
observed in all five groups. Approximately 5% (nine out of
197) of individuals exhibited extreme skewing (greater
than 40% deviation from a 50:50 distribution). However,
there was no difference between the groups, either in the
overall mean skewing, or in the fraction of individuals with
extreme skewing (>40%).
Androgen receptor gene allele size comparisons among
patients and controls
Although the present study was not initiated to examine
allelic variation in the AR gene per se, the data provide an
opportunity to address this question. Excessively long
CAG repeats in the AR gene are a rare cause of spinal-
bulbar muscular atrophy [13], and AR repeat length
appears to have an influence on the biology of certain
tumors [14,15]. In this context, it has been shown [16]
that transcription of the AR gene correlates inversely with
repeat length. We therefore compared AR repeat length in
control individuals and patients with autoimmunity. No dif-
ferences were observed for mean repeat length, or for
maximum and minimum repeat length, among the five
groups.
Discussion
The reason for the female predominance in most autoim-
mune diseases remains obscure. The present study was
initiated in order to address the hypothesis that a nonhor-
monal mechanism related to X inactivation might be
involved. The hypothesis rests on the idea that skewing of
X inactivation might lead to a deficiency of tolerance
induction in the thymus, particularly with respect to poly-
morphic X-linked autoantigens. The hypothesis predicts
that skewed X inactivation would be more prevalent in
females with autoimmune diseases than in female control
individuals. This was not observed.
Nevertheless, these negative data do not rule out a role for
X inactivation in female predisposition to loss of tolerance.
A general model for how this mechanism might operate is
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Figure 4
Fluorescence-based X-inactivation using PCR-based AR methylation assay. (a) An example of equivalent inactivation (51% versus 49%) of both
upper (271 bp) and lower (260 bp) alleles. (b) An example of extremely skewed inactivation (10% versus 90%) of the upper (284 bp) and lower
(271 bp) alleles. Mock-digested DNA (without HpaII) was used as control for peak intensities of both alleles.
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(a) (b)shown in Fig. 1. Thymocytes undergo selection in the
thymic parenchyma, and in the case of negative selection,
the selecting elements appear to be derived from the bone
marrow and consist mainly of thymic dendritic cells. If the
thymic dendritic cell population exhibits random X inactiva-
tion, it is highly likely that differentiating thymocytes will
contact dendritic cells that express self-antigens on both
X chromosomes. This situation is outlined schematically
on the left side of Fig. 2. However, if there is extremely
skewed X inactivation in the thymic dendritic cell popula-
tion, a particular thymocyte may not come into contact
with dendritic cells that express one of the two X chromo-
somes. This would lead to a situation where T cells may
undergo thymic maturation without having been negatively
selected for antigens that are expressed on the predomi-
nantly inactive X chromosome. This situation is shown on
the right side of Fig. 2.
In order for this mechanism to be physiologically relevant,
several assumptions must be made. First, defective toler-
ance from skewed X inactivation should only be directed
at X-linked antigens that are polymorphic, and for which
the individual is heterozygous. Thus, this mechanism
would not be expected to commonly lead to lack of toler-
ance unless there are at least several highly polymorphic
X-linked autoantigens in the population that are involved in
thymic deletion events. Second, if this actually leads to
autoimmunity, it also predicts that the initial break in toler-
ance that leads to disease should involve an X-linked
autoantigen that is expressed in a peripheral nontolerizing
site or circumstance.
A recent report [7] elegantly demonstrated the importance
of thymic deletion events in predisposing to autoimmune
disease. The PLP autoantigen is expressed in alternatively
spliced forms, which exhibit tissue-specific expression. A
nonspliced variant is expressed in periperal neural tissue.
However, in the thymus a splice variant results in the lack
of thymic expression of an immunodominant peptide. This
results in loss of tolerace of T cells to this peptide, pre-
sumably on the basis of lack of thymic deletion of thymo-
cytes that are reactive with this antigen. Interestingly, PLP
is encoded on the X chromsome. However, there is no evi-
dence that genetic polymorphisms control the level splic-
ing of PLP within the thymus. Nevertheless, these data
illustrate the potential importance of deficiencies in thymic
deletion for autoimmune T-cell reactivity.
The present results suggest that if skewed X inactivation
is relevant to induction of thymic tolerance, then the effect
does not depend on global skewing of X-chromosome
inactivation, at least in the hematopoietic compartment. In
this study we examined X-inactivation patterns in periph-
eral blood mononuclear cells, and the results should
reflect the state of X inactivation in all mesenchymal
tissues, including dendritic cells. X inactivation occurs at a
very early time point in development, and thus the results
in one tissue should reflect the general situation in the rest
of the body. However, there may be exceptions to this. We
have occasionally observed differences in X inactivation
patterns between buccal mucosa (an ectodermally derived
tissue) and peripheral blood (mesoderm) in the same indi-
vidual (unpublished observations). This could be a chance
event, or may result from selection for certain X-linked
alleles during embryonic development, as has been
described in carriers of X-linked immunodeficiencies [17].
However, in general, subsets of cells within the
hematopoietic compartment do not display differences in
X-inactivation patterns (unpublished observations).
Another consideration is that certain tissue microenviron-
ments may be derived from very small numbers of founder
cells, and thus may exhibit skewed utilization of one or the
other X chromosome, even if the tissue as a whole is not
skewed. This situation could vary over time. Thus, there may
be time points at which certain thymic microenvironments
are populated by dendritic cells that, for stochastic reasons,
all utilize the same X chromosome. This would create a
‘window of opportunity’ in which a given thymocyte, in a
given selecting location, could escape negative selection by
antigens on the inactive X chromosome. The likelihood of
this happening would obviously depend on the number of
dendritic cells that are usually contacted by a thymocyte
during thymic selection. There is limited information on this
point, although Stewart [10] has theorized that this number
may be as low as 15. If this is the case, escape from thymic
deletion may still occur in females who are heterozygous for
a relevant X-linked antigen, even if the hematopoietic cells in
general do not exhibit extreme skewing.
If the latter scenario is operative, it will be extremely difficult
to document it by studying X-inactivation patterns. One
might examine X-inactivation skewing specifically in thymic
dendritic populations, but if the effect is at the level of
microenvironment and varies over time, then it will not be
possible to detect this using methods directed at large cell
populations, as we have done here. Conceivably, examina-
tion of thymic tissue sections could provide support for the
hypothesis. Another aspect of this is that some thymic
deletion events appear to be mediated by thymic epithelial
cells at the cortico-medullary junction. Interestingly, thymic
epithelial cells appear to be derived from very few founder
cells [18], and thus should exhibit a rather large degree of
‘patchiness’ with respect to X inactivation. This again might
lead to local epithelial cell microenvironments that fail to
delete for X-linked autoantigens.
It has recently become apparent that mechanisms of
peripheral tolerance also exist, and we have considered
the possibility that skewed X inactivation in a peripheral
tolerizing compartment might also lead to inefficient
tolerance. A major mechanism of peripheral tolerance
http://arthritis-research.com/content/2/5/399induction appears to involve the recognition of tolerizing
antigens by T cells in the absence of costimulation [19].
This may specifically occur in the paracortical regions of
lymph nodes, without further progression of the tolerized T
cells into lymph node follicles. Because this mechanism
presumably involves circulating antigen, it is difficult to
invoke a role for X-inactivation skewing in altering this
process, unless the skewing were virtually complete. Tol-
erance induction by parenchymal tissue has also been
described [20], and may be a multistage process that is
still not entirely understood. Conceivably, skewed expres-
sion of X-linked autoantigens could play a role here, but
this would require invoking a peripheral tolerizing compart-
ment that is limiting with respect to the dosage of toleriz-
ing cells to which peripheral T cells can be exposed. No
such compartment has yet been defined.
In conclusion, we suggest that X-chromosome inactivation
needs to be considered as a potential factor in the pre-
dominance of females in most autoimmune diseases. Our
inability to show an increase in X-chromosome skewing in
females with autoimmunity does not eliminate this as an
etiologic contributor to loss of immunologic tolerance.
Future experiments must be directed at detailed analysis
of tissue patterns of X inactivation, as well as at a search
for potential X-linked autoantigens.
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